Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $8.68, but opened at $10.20. Gyre Therapeutics shares last traded at $11.06, with a volume of 650,562 shares.
Analysts Set New Price Targets
Separately, Noble Financial assumed coverage on shares of Gyre Therapeutics in a report on Tuesday, March 11th. They set an "outperform" rating on the stock.
Read Our Latest Analysis on Gyre Therapeutics
Gyre Therapeutics Price Performance
The firm has a market cap of $886.95 million, a PE ratio of 473.00 and a beta of 1.90. The business's fifty day moving average is $8.97 and its 200-day moving average is $10.56.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported $0.03 earnings per share for the quarter, meeting analysts' consensus estimates of $0.03. The business had revenue of $22.06 million for the quarter, compared to the consensus estimate of $28.40 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.
Institutional Trading of Gyre Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in GYRE. Wells Fargo & Company MN boosted its holdings in Gyre Therapeutics by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock worth $49,000 after purchasing an additional 913 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Gyre Therapeutics by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company's stock worth $1,386,000 after buying an additional 918 shares in the last quarter. Barclays PLC lifted its holdings in Gyre Therapeutics by 13.5% in the 4th quarter. Barclays PLC now owns 10,543 shares of the company's stock worth $128,000 after purchasing an additional 1,255 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Gyre Therapeutics by 11.1% during the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company's stock worth $168,000 after acquiring an additional 1,389 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Gyre Therapeutics by 15,083.3% during the first quarter. GAMMA Investing LLC now owns 1,822 shares of the company's stock valued at $140,000 after purchasing an additional 1,810 shares in the last quarter. Hedge funds and other institutional investors own 23.99% of the company's stock.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Read More
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
